181 related articles for article (PubMed ID: 37267517)
21. Novel targeted therapies for mantle cell lymphoma.
Alinari L; Christian B; Baiocchi RA
Oncotarget; 2012 Feb; 3(2):203-11. PubMed ID: 22361516
[TBL] [Abstract][Full Text] [Related]
22. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T; Evans CM; Zakheim D; Chu KL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; Chen Z; Fennell M; Garippa R; Seshan V; de Stanchina E; Barbash O; Batlevi CL; Leslie CS; Melnick AM; Younes A; Kharas MG
Nat Commun; 2022 Sep; 13(1):5676. PubMed ID: 36167829
[TBL] [Abstract][Full Text] [Related]
23. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma.
Jacobson C; Kopp N; Layer JV; Redd RA; Tschuri S; Haebe S; van Bodegom D; Bird L; Christie AL; Christodoulou A; Saur A; Tivey T; Zapf S; Bararia D; Zimber-Strobl U; Rodig SJ; Weigert O; Weinstock DM
Blood; 2016 Nov; 128(21):2517-2526. PubMed ID: 27742706
[TBL] [Abstract][Full Text] [Related]
24. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma.
Chiarle R; Budel LM; Skolnik J; Frizzera G; Chilosi M; Corato A; Pizzolo G; Magidson J; Montagnoli A; Pagano M; Maes B; De Wolf-Peeters C; Inghirami G
Blood; 2000 Jan; 95(2):619-26. PubMed ID: 10627471
[TBL] [Abstract][Full Text] [Related]
25. Concurrent inhibition of PI3K and mTORC1/mTORC2 overcomes resistance to rapamycin induced apoptosis by down-regulation of Mcl-1 in mantle cell lymphoma.
Müller A; Zang C; Chumduri C; Dörken B; Daniel PT; Scholz CW
Int J Cancer; 2013 Oct; 133(8):1813-24. PubMed ID: 23580240
[TBL] [Abstract][Full Text] [Related]
26. P110α-mediated constitutive PI3K signaling limits the efficacy of p110δ-selective inhibition in mantle cell lymphoma, particularly with multiple relapse.
Iyengar S; Clear A; Bödör C; Maharaj L; Lee A; Calaminici M; Matthews J; Iqbal S; Auer R; Gribben J; Joel S
Blood; 2013 Mar; 121(12):2274-84. PubMed ID: 23341541
[TBL] [Abstract][Full Text] [Related]
27. Aggressive morphologic variants of mantle cell lymphoma characterized with high genomic instability showing frequent chromothripsis, CDKN2A/B loss, and TP53 mutations: A multi-institutional study.
Streich L; Sukhanova M; Lu X; Chen YH; Venkataraman G; Mathews S; Zhang S; Kelemen K; Segal J; Gao J; Gordon L; Chen Q; Behdad A
Genes Chromosomes Cancer; 2020 Aug; 59(8):484-494. PubMed ID: 32277542
[TBL] [Abstract][Full Text] [Related]
28. Response and resistance to CDK12 inhibition in aggressive B-cell lymphomas.
Gao J; Wang MY; Ren Y; Lwin T; Li T; Yan JC; Sotomayor EM; Duckett DR; Shah BD; Shain KH; Zhao X; Tao J
Haematologica; 2022 May; 107(5):1119-1130. PubMed ID: 34162179
[TBL] [Abstract][Full Text] [Related]
29. Protein arginine methyltransferase 5 (PRMT5) inhibition induces lymphoma cell death through reactivation of the retinoblastoma tumor suppressor pathway and polycomb repressor complex 2 (PRC2) silencing.
Chung J; Karkhanis V; Tae S; Yan F; Smith P; Ayers LW; Agostinelli C; Pileri S; Denis GV; Baiocchi RA; Sif S
J Biol Chem; 2013 Dec; 288(49):35534-47. PubMed ID: 24189068
[TBL] [Abstract][Full Text] [Related]
30. Phosphoinositide-dependent protein kinase 1 is a potential novel therapeutic target in mantle cell lymphoma.
Maegawa S; Chinen Y; Shimura Y; Tanba K; Takimoto T; Mizuno Y; Matsumura-Kimoto Y; Kuwahara-Ota S; Tsukamoto T; Kobayashi T; Horiike S; Taniwaki M; Kuroda J
Exp Hematol; 2018 Mar; 59():72-81.e2. PubMed ID: 29287939
[TBL] [Abstract][Full Text] [Related]
31. Modulation of p73 isoforms expression induces anti-proliferative and pro-apoptotic activity in mantle cell lymphoma independent of p53 status.
Hassan HM; Varney ML; Chaturvedi NK; Joshi SS; Weisenburger DD; Singh RK; Dave BJ
Leuk Lymphoma; 2016 Dec; 57(12):2874-2889. PubMed ID: 27074052
[TBL] [Abstract][Full Text] [Related]
32. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma.
Balsas P; Palomero J; Eguileor Á; Rodríguez ML; Vegliante MC; Planas-Rigol E; Sureda-Gómez M; Cid MC; Campo E; Amador V
Blood; 2017 Jul; 130(4):501-513. PubMed ID: 28533307
[TBL] [Abstract][Full Text] [Related]
33. PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers.
Li Y; Chitnis N; Nakagawa H; Kita Y; Natsugoe S; Yang Y; Li Z; Wasik M; Klein-Szanto AJ; Rustgi AK; Diehl JA
Cancer Discov; 2015 Mar; 5(3):288-303. PubMed ID: 25582697
[TBL] [Abstract][Full Text] [Related]
34. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression.
Liu H; Lu Z; Shi X; Liu L; Zhang P; Golemis EA; Tu Z
J Biol Chem; 2021 Aug; 297(2):100996. PubMed ID: 34302809
[TBL] [Abstract][Full Text] [Related]
35. The mTOR kinase inhibitor everolimus synergistically enhances the anti-tumor effect of the Bruton's tyrosine kinase (BTK) inhibitor PLS-123 on Mantle cell lymphoma.
Li J; Wang X; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Pan Z; Ding N; Song Y; Zhu J
Int J Cancer; 2018 Jan; 142(1):202-213. PubMed ID: 28905990
[TBL] [Abstract][Full Text] [Related]
36. Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Moosburner M; Alibegovic L; Hasselmann K; Gaiderov A; Hildebrand J; Philippou-Massier J; Blum H; Fischer L; Dreyling M; Silkenstedt E
Hematol Oncol; 2023 Dec; 41(5):858-868. PubMed ID: 37300279
[TBL] [Abstract][Full Text] [Related]
37. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib.
Kagiyama Y; Fujita S; Shima Y; Yamagata K; Katsumoto T; Nakagawa M; Honma D; Adachi N; Araki K; Kato A; Inaki K; Ono Y; Fukuhara S; Kobayashi Y; Tobinai K; Kitabayashi I
Cancer Sci; 2021 Jun; 112(6):2314-2324. PubMed ID: 33792119
[TBL] [Abstract][Full Text] [Related]
38. The Serum- and Glucocorticoid-Inducible Kinase 1 (SGK1) as a Novel Therapeutic Target in Mantle Cell Lymphoma.
Li J; Yu H; Wang X; Ye Y; Fang W; Ding N; Mi L; Ping L; Wang X; Song Y; Zhu J
Cancer Control; 2022; 29():10732748221143881. PubMed ID: 36519740
[TBL] [Abstract][Full Text] [Related]
39. PRMT1 loss sensitizes cells to PRMT5 inhibition.
Gao G; Zhang L; Villarreal OD; He W; Su D; Bedford E; Moh P; Shen J; Shi X; Bedford MT; Xu H
Nucleic Acids Res; 2019 Jun; 47(10):5038-5048. PubMed ID: 30916320
[TBL] [Abstract][Full Text] [Related]
40. Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.
Yoshimura M; Ishizawa J; Ruvolo V; Dilip A; Quintás-Cardama A; McDonnell TJ; Neelapu SS; Kwak LW; Shacham S; Kauffman M; Tabe Y; Yokoo M; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2014 Jul; 105(7):795-801. PubMed ID: 24766216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
